

# **Written Comments Received**

**#1 Vincent Chairez**

## Damoth, Debbie@DCA

---

**From:** Vincent Chairez <vchairezbusiness@gmail.com>  
**Sent:** Monday, January 27, 2025 9:58 AM  
**To:** Damoth, Debbie@DCA  
**Subject:** Re: Public Comment

### This Message Is From an External Sender

WARNING: This email originated from outside of the organization! Do not click links, open attachments, or reply, unless you recognize the sender's email.

[Report Suspicious](#)

Hello Debbie

I know last time I emailed you, it wasn't within the two business days as required for comments to the full Board. I like to reiterate my comment with one small clarification for the next full board meeting.

Hello

My name is Vincent Chairez, pharmacy technician at CVS #8839

I respectfully ask the board to consider monitoring the prescribing use of Gabapentin and possibly changing it to a Schedule 5.

At the retail level, I'm seeing a significant increase of patients being prescribed

- at or near the highest daily dosage amount recommended
- in conjunction with other benzodiazepines, opioids, and sedative-hypnotics as a normal therapy combination.
- more pain management patients eager for an early refill

These concerns have been confirmed and endorsed by UFCW CVS Pharmacists as a growing issue.

On Mon, Jan 6, 2025 at 9:04 AM Damoth, Debbie@DCA <[Debbie.Damoth@dca.ca.gov](mailto:Debbie.Damoth@dca.ca.gov)> wrote:

Hello Vincent, Your comment was received and will be posted like the attached document.  
Thank you, Debbie



**Debbie Damoth**, Executive Specialist Manager

California State Board of Pharmacy

(916) 518-3090 | FAX (916) 574-8614 | [www.pharmacy.ca.gov](http://www.pharmacy.ca.gov)

**Be Aware and Take Care: Talk to your Pharmacist!**

---

**From:** Vincent Chairez <[vchairezbusiness@gmail.com](mailto:vchairezbusiness@gmail.com)>  
**Sent:** Monday, January 6, 2025 8:52 AM  
**To:** Damoth, Debbie@DCA <[Debbie.Damoth@dca.ca.gov](mailto:Debbie.Damoth@dca.ca.gov)>  
**Subject:** Re: Public Comment

My comment

Hello

My name is Vincent Chairez, pharmacy technician at CVS #8839

I respectfully ask the board to consider monitoring the prescribing use of Gabapentin and possibly changing it to a Schedule 5.

At the retail level, I'm seeing a significant increase of patients being prescribed

- at or near the highest daily dosage amount recommended
- in conjunction with other benzodiazepines, opioids, and sedative-hypnotics as a normal therapy combination.
- more pain management patients eager for that early refill

On Mon, Jan 6, 2025 at 8:06 AM Damoth, Debbie@DCA <[Debbie.Damoth@dca.ca.gov](mailto:Debbie.Damoth@dca.ca.gov)> wrote:

Good morning, You may submit your comments in writing to me. The comments are forwarded to Board Members and then posted on the Board's website for meeting materials as written comments received. The Board respectfully requests additional written comments be sent two days before the meeting to allow for distribution. Best Regards,



**Debbie Damoth**, Executive Specialist Manager  
California State Board of Pharmacy  
(916) 518-3090 | FAX (916) 574-8614 | [www.pharmacy.ca.gov](http://www.pharmacy.ca.gov)

**Be Aware and Take Care: Talk to your Pharmacist!**

---

**From:** Vincent Chairez <[vchairezbusiness@gmail.com](mailto:vchairezbusiness@gmail.com)>  
**Sent:** Sunday, January 5, 2025 4:27 PM  
**To:** Damoth, Debbie@DCA <[Debbie.Damoth@dca.ca.gov](mailto:Debbie.Damoth@dca.ca.gov)>  
**Subject:** Public Comment

Hello,

My name is Vincent Chairez.

Pharmacy Technician at CVS #8839

Is there a way to email a public comment ahead of the Full Board meeting?

If you prefer to call me, my number is 310.874.4711

Thank You